Enobia Raises $40M for Hypophosphatasia Candidate Development

Data from the study in juveniles confirmed therapy using ENB-0040 led to significant improvements in rickets in treated patients.

Enobia Pharma raised $40 million in a private placement to fund further development of its Phase II-stage enzyme replacement therapy (ERT) ENB-0040 for the genetic bone disorder hypophosphatasia.

Enobia was in addition recently awarded a $1.2 million, three-year FDA orphan grant to support development of ENB-0040 for the long-term treatment of infants and young children with hypophosphatasia.

The genetic bone disorder hypophosphatasia is caused by deficiency in a tissue-nonspecific form of alkaline phosphatase (TNSALP), and causes inorganic pyrophosphate to accumulate in the extracellular space and inhibit skeletal mineralization, leading to rickets in pediatric patients and osteomalacia in adults.